CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 3.45: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.38%
Annual Rate
CNY 0.02Paid unknown
Payout Ratio
134.1%High
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.60BCNY388.06M · vs all stocks (USD)
Revenue (TTM)
282.31MCNY42.13M · vs all stocks (USD)
Profit Margin
-2.95%vs Biotechnology peers
Beta
0.5270xvs all stocks
52-Week Change
-39.17%vs all stocks
Forward Annual Dividend Yield
0.38%vs all stocks
Market Capitalization
2.60BCNY388.06M · vs all stocks (USD)
Enterprise Value
2.49BCNY371.04M · vs all stocks (USD)
Price to Sales (TTM)
9.21xvs Biotechnology peers
Price to Book (MRQ)
2.97xvs Biotechnology peers
Enterprise to Revenue
8.81xvs Biotechnology peers
Enterprise to EBITDA
56.46xvs Biotechnology peers
Gross Margin
61.56%vs Biotechnology peers
Profit Margin
-2.95%vs Biotechnology peers
Operating Margin
0.42%vs Biotechnology peers
Return on Assets (TTM)
0.36%vs Biotechnology peers
Return on Equity (TTM)
-0.67%vs Biotechnology peers
Revenue (TTM)
282.31MCNY42.13M · vs all stocks (USD)
Revenue per Share (TTM)
0.6150CNYUpdated Sep 21, 2026Quarterly Revenue Growth
18.00%vs Biotechnology peers
Gross Profit (TTM)
171.18MCNY25.54M · vs all stocks (USD)
EBITDA (TTM)
64.84MCNY9.68M · vs all stocks (USD)
Net Income (TTM)
-8.32MCNY-1.24M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
43.33%vs Biotechnology peers
Operating Cash Flow (TTM)
61.02MCNY9.11M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-84.33MCNY-12.58M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0200CNYUpdated Sep 21, 2026Forward Annual Dividend Yield
0.38%vs all stocks
Trailing Annual Dividend Rate
0.0250CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.40%vs all stocks
Payout Ratio
134.15%vs Biotechnology peers
Minority Interest (Equity)
3.60MCNYFY2025 · Dec 31, 2025Revenue
263.23MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
94.81MCNYFY2025 · Dec 31, 2025Gross Profit
168.42MCNYFY2025 · Dec 31, 2025Operating Income
26.44MCNY3.95M · vs all stocks (USD)
Pre-tax Income
13.29MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.18MCNYFY2025 · Dec 31, 2025Net Income
15.47MCNYFY2025 · Dec 31, 2025EBIT
39.78MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
64.84MCNYFY2025 · Dec 31, 2025Research & Development
41.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
42.14MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.85MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.21MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
26.49MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
458.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
458.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
15.47MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.72MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-1.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
-18.29MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
335.98MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
15.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
27.20MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-23.69MCNYFY2025 · Dec 31, 2025Capital Expenditures
-16.72MCNYFY2025 · Dec 31, 2025Net Acquisitions
359.14KCNYFY2025 · Dec 31, 2025Purchase of Investments
-17.00MCNYFY2025 · Dec 31, 2025Sale of Investments
25.77MCNYFY2025 · Dec 31, 2025Other Investing Activity
46.10MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
38.51MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
26.69MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-40.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.86MCNYFY2025 · Dec 31, 2025Other Financing Charges
640.00KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-27.52MCNYFY2025 · Dec 31, 2025Shares Outstanding
405.08MSharesUpdated Sep 21, 2026Float Shares
150.35MSharesUpdated Sep 21, 2026% Held by Insiders
63.36%vs all stocks
% Held by Institutions
1.85%vs all stocks
Total Cash (MRQ)
584.16MCNY87.17M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.44CNYUpdated Sep 21, 2026Total Debt (MRQ)
463.65MCNY69.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5266xvs Biotechnology peers
Current Ratio (MRQ)
6.61xvs Biotechnology peers
Book Value per Share (MRQ)
2.16CNYUpdated Sep 21, 2026Total Assets
1.52BCNY227.49M · vs all stocks (USD)
Total Current Assets
817.81MCNYFY2025 · Dec 31, 2025Total Liabilities
616.87MCNYFY2025 · Dec 31, 2025Total Non-current Assets
706.73MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
456.16MCNYFY2025 · Dec 31, 2025Total Current Liabilities
160.70MCNYFY2025 · Dec 31, 2025Cash
335.31MCNYFY2025 · Dec 31, 2025Cash Equivalents
57.53MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
392.84MCNYFY2025 · Dec 31, 2025Other Short-term Investments
235.30MCNYFY2025 · Dec 31, 2025Accounts Receivable
110.21MCNYFY2025 · Dec 31, 2025Inventory
54.77MCNYFY2025 · Dec 31, 2025Accounts Payable
72.96MCNYFY2025 · Dec 31, 2025Short-term Debt
34.55MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.14MCNYFY2025 · Dec 31, 2025Long-term Debt
413.00MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
405.07MCNYFY2025 · Dec 31, 2025Retained Earnings
160.24MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
907.68MCNY135.44M · vs all stocks (USD)
52-Week Low
5.55CNYUpdated Sep 21, 202652-Week High
11.50CNYUpdated Sep 21, 202652-Week Change
-39.17%vs all stocks
Beta
0.5270xvs all stocks
50-Day MA
6.45CNYUpdated Sep 21, 2026200-Day MA
7.97CNYUpdated Sep 21, 2026Avg 10-Day Volume
4.65MSharesUpdated Sep 21, 2026Avg 30-Day Volume
8.35MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.0200CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: -0.03
Financial Health
Altman Z-Score 3.45: safe zoneNotable
Altman Z-Score: 3.45
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule